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PPRE-CLINICAL RESEARCH
Human Peripheral Blood-Derived CD31 Cells
Have Robust Angiogenic and Vasculogenic Properties
and Are Effective for Treating Ischemic Vascular Disease
Sung-Whan Kim, PHD,* Hyongbum Kim, MD, PHD,* Hyun-Jai Cho, MD, PHD,†
Jung-Uek Lee, MS,‡ Rebecca Levit, MD,* Young-sup Yoon, MD, PHD*
Atlanta, Georgia; Seoul, South Korea; and Los Angeles, California
Objectives This study aimed to determine if CD31 is a novel marker of a circulating angio-vasculogenic cell population and
to establish the cells’ therapeutic effects on experimental ischemia.
Background Emerging evidence suggested that therapeutic mechanisms underlying various bone marrow-derived cells are
due to paracrine effects. Furthermore, the vasculogenic potential of these cells is under debate. CD31 is a well-
known marker for endothelial cells but is also expressed in a fraction of peripheral blood (PB) mononuclear
cells.
Methods CD31 cells were isolated from human PB by magnetic-activated cell sorting. The gene expression profile
was examined by deoxyribonucleic acid microarray and real-time reverse transcriptase polymerase chain
reaction. Various in vitro endothelial differentiation or vasculogenic assays were conducted. Finally, cells
were directly implanted into a mouse hind limb ischemia model to test angiogenic-vasculogenic and thera-
peutic effects.
Results Fluorescent-activated cell sorter analysis revealed that PB-CD31 cells exhibited endothelial and hematopoietic
stem/progenitor markers. CD31 cells had higher levels of expression of proangiogenic genes on microarray
and real-time reverse transcriptase polymerase chain reaction and generated higher numbers of endothelial pro-
genitor cells than CD31– cells did. CD31 cells spontaneously formed vascular tubelike structures and exhibited
an endothelial cell phenotype in vitro. In a hind limb ischemia model, CD31 cell transplantation augmented
blood perfusion and prevented limb loss. Both angiogenic cytokines and capillary density were increased, sug-
gesting CD31 cells augmented neovascularization.
Conclusions CD31 is a novel marker that designates circulating angiogenic and vasculogenic cells. These cells are easily iso-
lated from human PB and thus are a novel candidate for treatment of ischemic cardiovascular disease. (J Am
Coll Cardiol 2010;56:593–607) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.070b
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vschemic cardiovascular disease is the most prevalent disease
n Westernized society. Despite progress in therapies, nearly
0 million are affected yearly from heart attack, stroke, and
schemic cardiomyopathy (1). As our knowledge of stem cell
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rogram funded by the Ministry of Education, Science and Technology, Republic of
orea; an overseas post-doctoral fellowship grant from the Korea Research Founda-
ion, Republic of Korea (MOEHRD, to Dr. S.-W. Kim); and an Atlanta Clinical
ranslational Research Institute (ACTSI)–Georgia Tech Emory Collaboration for
egenerative Medicine and Engineering (GTEC) pilot grant. The authors have
eported that they have no relationships to disclose.t
Manuscript received August 20, 2009; revised manuscript received January 4, 2010,
ccepted January 11, 2010.iology grows, cell-based therapies have become a promis-
ng strategy for tissue regeneration. Transplantation of
arious bone marrow (BM)–derived cells, including mono-
uclear cells (MNCs), endothelial progenitor cells (EPCs),
esenchymal stem cells, and hematopoietic stem cells
See page 608
HSCs), were reported to induce therapeutic neovascular-
zation in adult ischemic tissues (2–5). Even though cell-
ased therapy has great therapeutic potential, several issues
emain. The use of unselected BM cells or BM-MNCs was
ssociated with adverse events including calcification, vas-
ular plaque growth, and worsening of tissue ischemia
6–8). Both EPCs and mesenchymal stem cells require ex
ivo culture to be used clinically. For all BM-derived cells,
heir ability to (trans)differentiate into endothelial cells
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Angio-Vasculogenic Properties of CD31 Cells August 10, 2010:593–607(ECs), and the magnitude of their
vasculogenic potential, have been
debated (9–11). Paracrine mecha-
nisms and/or other nondifferentia-
tion effects are the primary medi-
ators of BM-derived cell benefit in
ischemic cardiovascular disease
(3,12–14) and mainly work via
augmentation of neovasculariza-
tion/angiogenesis or improvement
of microcirculation.
Based on these new discoveries
on the mechanisms and adverse
effects of various BM cells over the
past decade, in this study, we
sought to explore whether there is
a specific native population of BM
cells that possesses higher para-
crine or angiogenic activity and,
further, to determine the thera-
peutic potential of this population
for treating ischemic cardiovascu-
lar diseases. Additionally, given
the controversy regarding the
(trans)differentiation, we sought to
definitively determine whether
BM cells are able to give rise to
ECs via vasculogenesis. We used
rigorous criteria and new experi-
mental techniques to address the
main points of criticism from the
revious studies that refuted the concept of endothelial differ-
ntiation from BM cells (9–11,15).
We have found that CD31, a ubiquitous EC marker, is
lso expressed on the surface of various mouse hematopoi-
tic cell lineages (16), including HSCs (17), and undiffer-
ntiated mouse embryonic stem cells (18). CD31, also
nown as platelet endothelial cell adhesion molecule 1, is a
30-kDa cell surface molecule and a member of the immu-
oglobulin superfamily (19). CD31 plays important role for
ransendothelial leukocyte migration, cell-cell adhesion, and
ntiapoptotic signaling (20). However, the therapeutic role
f the cells expressing this marker in tissue regeneration is
nknown. Based on the conserved expression of CD31 on
ells of the hemangioblast lineage, we hypothesized that
D31 cells in peripheral blood (PB) have higher angio-
enic and/or vasculogenic capabilities.
Through a series of in vitro and in vivo experiments, we
ound that CD31 cells isolated from PB showed higher
ngiogenic activity and vasculogenic potential, effectively
mproving ischemia in mouse hind limb ischemia by aug-
entation of neovascularization.
ethods
n expanded Methods section is available in the Online
Abbreviations
and Acronyms
BM  bone marrow
DiI-acLDL 
1,1=dioctadecyl-3,3,3=,3=-
tetramethylindocarbocyanine-
labeled acetylated low-
density lipoprotein
EC  endothelial cell
EPC  endothelial
progenitor cell
FACS  fluorescent-
activated cell sorter
FISH  fluorescent in situ
hybridization
HPC  hematopoietic
progenitor cell
HSC  hematopoietic stem
cell
ILB4  isolectin B4
MCP  monocyte
chemoattractant protein
MNC  mononuclear cell
PB  peripheral blood
PBS  phosphate-buffered
saline
qRT-PCR  quantitative
real-time reverse
transcriptase polymerase
chain reactionppendix. The following topics are covered there: O• Isolation and culture of CD31 cells
• Flow cytometry
• Microarray analysis
• Quantitative real-time reverse transcriptase polymerase
chain reaction (qRT-PCR)
• EPC culture assay and immunocytochemistry
• Cell adhesion assay
• Hematopoietic colony forming unit assays
• Transplantation of the CD31 and CD31– cells into
ischemic hind limb
• Histological analysis
• Fluorescent-activated cell sorter (FACS) analysis of
ECs derived from transplanted CD31 cells
• Statistical analysis
esults
ndothelial and hematopoietic stem cell characteristics
f PB-CD31 cells. The FACS analysis on PB-CD31
ells showed that 95% of magnetic-activated cell sorting–
solated CD31 cells express CD31 (Fig. 1A). Approxi-
ately 40% of CD31 cells expressed CD14, a monocyte/
acrophage marker and more than 99% of CD31 cells
xpressed CD45, a pan-hematopoietic marker; this suggests
hat CD31 cells are not circulating ECs (Figs. 1A and
C). CD31 cells preferentially expressed endothelial
arkers (CD105, CD141, CD144, and von Willebrand
actor; p 0.05) and stem cell or progenitor markers (CD34,
D133, CD117, and kinase insert domain receptor [vascular
ndothelial growth factor receptor 2]; p  0.05) (Fig. 1B,
nline Fig. 1A). To investigate the hematopoietic progenitor
ell (HPC) properties, a clonogenic assay was performed.
D31 cells, when compared with CD31– cells, generated a
ignificantly higher number of hematopoietic colonies such as
olony forming unit erythroid, burst forming unit erythroid,
olony forming unit granulocyte/macrophage, and colony
orming unit granulocyte/erythroid/macrophage/megakary-
cyte (p  0.05) (Fig. 1C, Online Fig. 1B). These data
how that CD31 cells have characteristics of HSC/HPCs
s well as ECs.
nriched angiogenic, cell adhesion, and chemoattraction
enes in CD31 cells. To compare global gene expression
atterns between CD31 and CD31– cells, we carried out
icroarray analysis. Hierarchical cluster analysis showed
hat gene expression in CD31 cells are distinct from
D31– cells in that 749 genes were up-regulated and 26
enes were down-regulated by more than 2-fold in the
D31 cells than in CD31– cells (Fig. 2A). Further
haracterization with the Gene Ontology Database (21)
emonstrated that genes involved in angiogenesis, cell
dhesion, transmembrane structure, chemokine production
nd reception, and extracellular matrix were highly and
referentially expressed in CD31 cells (Fig. 2B, Table 1,
nline Tables S1 to S3) (22).
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August 10, 2010:593–607 Angio-Vasculogenic Properties of CD31 CellsTo confirm the results of microarray data, we performed
RT-PCR analysis. Major angiogenic factors such as vas-
ular endothelial growth factor-A, fibroblast growth
Figure 1 Hematopoietic and Endothelial Characteristics of PB
(A) Magnetic-activated cell sorted CD31 and CD31– cells were analyzed by fluorescent-aactor-2, hepatocyte growth factor, and angiopoietin-1, and pn adhesion molecule, VE-cadherin, were more highly
xpressed in CD31 cells than in CD31– cells or MNCs
Fig. 2C). Chemokines such as monocyte chemoattractant
 Cells
d cell sorter for hematopoietic and endothelial cell markers. Continued on next page.CD31
ctivaterotein-1 and interleukin-8, which play an important role
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Angio-Vasculogenic Properties of CD31 Cells August 10, 2010:593–607or neovascularization, were also significantly up-regulated
23,24). Collectively, these findings show that CD31 cells
efine a population enriched with angiogenic, chemoattrac-
ant, and cell adhesion genes.
D31 cells show higher vasculogenic potential and cell
dhesion capacity in vitro. We next investigated the in
itro endothelial differentiation potential of CD31 cells.
irst, we performed EPC culture assay. The number of EPCs
nd EPC colonies were markedly higher in the CD31 cell
roup than in the CD31– cell group (all p  0.01) (Figs. 3A
nd 3B). Second, we carried out a cell adhesion assay.
he number of adhered cells to various extracellular
atrix proteins, fibronectin, vitronectin, collagen I, and
aminin was significantly higher in the CD31 cells than
n the CD31– cells (all p  0.001) (Fig. 3C). In ECs,
dhesion capacity is an indicator of cell engraftment and
ell survival.
To induce EC differentiation, CD31 cells were cultured
n endothelial growth media 2, which is endothelia cell basal
edia 2 with 15% FBS and cytokine cocktail (SingleQuots,
Figure 1 Continued
(B) Quantification of the fluorescent-activated cell sorter data for CD31 and CD3
endothelial cell markers in CD31 cells. n  4 per group. (C) In vitro hematopoie
activities were higher in the CD31 group. n  5 per group. *p  0.05; **p  0.
GEMM  colony forming unit granulocyte/erythroid/macrophage/megakaryocyte; C
receptor; vWF  von Willebrand factor.onza Cologne AG, Cologne, Germany), for 28 days. aD31 cells exhibited EC markers such as von Willebrand
actor, kinase insert domain receptor, vascular endothelial
adherin, and CD31 by immunocytochemistry (Fig. 3D).
D31– cells were not culturable under these conditions.
uring this culture, we made an intriguing observation
hat some CD31 cells spontaneously formed tubular
tructures. In the first week of culture, CD31 cells
ggregated; around day 10, the cells started to form
ubular structures within the cell clusters; and between
ays 12 and 16, the cell clusters underwent morphologic
hanges to form linear tubular structures, mimicking in
ivo vasculogenesis (Figs. 3E to 3I). These tubular
tructures stained positive for lectin and took up
,1=dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine-
abeled acetylated low-density lipoprotein (DiI-acLDL),
haracteristics of ECs. We further measured the expres-
ion of endothelial and angiogenic genes during the
ulture of CD31 cells over 28 days by qRT-PCR. Over
8 days, the expression of kinase insert domain receptor,
ascular endothelial cadherin, hepatocyte growth factor,
s showing enriched expression of monocyte, hematopoietic stem/progenitor, and
genitor cell assay of CD31 and CD31– cells. The hematopoietic progenitor cell
U-E  burst forming unit erythroid; CFU-E  colony forming unit erythroid; CFU-
 colony forming unit granulocyte/macrophage; KDR  kinase insert domain1– cell
tic pro
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August 10, 2010:593–607 Angio-Vasculogenic Properties of CD31 Cellsesting differentiation into a more vasculogenic and
ngiogenic phenotype (Fig. 3J). Together, these data
emonstrate the vasculogenic and angiogenic potential of
D31 cells in vitro.
D31 cells exert favorable therapeutic effects on hind
imb ischemia. After identifying the angiogenic and vas-
ulogenic characteristics of CD31 cells in vitro, we inves-
Figure 2 The Gene Expression Profile and GO-Scan Classificatio
(A) Hierarchical cluster analysis. Gene expression profiling of CD31 and CD31– c
set. Red signifies increased expression and blue signifies decreased expression. (
egory of annotations from our list of 779 genes (generated using multiple compar
terns of multiple angiogenic factors were measured by real-time reverse transcript
the mononuclear cell group. n  6 per group. *p  0.05; **p  0.01. ANG  an
aldehyde-3-phosphate dehydrogenase; HGF  hepatocyte growth factor; IGF  ins
MNC  mononuclear cell; PDGF-B  platelet-derived growth factor B; VE-cad igated the therapeutic potential of CD31 cells to repair (xperimentally induced ischemia in vivo. Laser Doppler
erfusion image analysis demonstrated that blood perfusion
as significantly higher in the CD31 cell-injected limbs
ersus CD31– cell- or phosphate-buffered saline (PBS)–
njected limbs at days 7, 14, and 21 (Figs. 4A and 4B). The
D31 cell-treated group showed a significantly lower limb
oss score than the PBS control group did (p  0.05)
Differentially Expressed Genes
ach column represents 3 CD31 and CD31– cells and each row reflects a probe
e x axis represents the number of differentially expressed genes in a specific cat-
orrection: false-discovery rate adjusted p value 0.05). (C) The expression pat-
lymerase chain reaction. Data are presented as fold difference compared with
tin; FDR  false-discovery rate; FGF  fibroblast growth factor; GAPDH  glycer-
e growth factor; IL  interleukin; MCP  monocyte chemoattractant protein;
lar endothelial cadherin; VEGF  vascular endothelial growth factor.n of
ells. E
B) Th
isons c
ase po
giopoie
ulinlik
vascuFigs. 4C and 4D). The capillary density and vascular
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Angio-Vasculogenic Properties of CD31 Cells August 10, 2010:593–607aturation in the ischemic hind limb adductor muscle after
urgery was also significantly higher in the CD31 group
han in the CD31– group or the PBS group (p  0.01)
Figs. 5A and 5B, Online Fig. 2). We also found that
unctional capillaries examined after intracardiac injection
f isolectin B4 (ILB4) were significantly higher in the
D31 group than in the other groups (Online Fig. 3).
n addition, terminal deoxyribonucleotidyl transferase
TDT)-mediated dUTP-digoxigenin nick end labeling
TUNEL) assay, together with ILB4 staining, demon-
trated that transplantation of CD31 cells significantly
educed endothelial cell apoptosis when compared to
ontrol groups, suggesting protective effects on existing
essels (Online Fig. 4). Collectively, these findings sug-
est that CD31 cells can augment functional neovascu-
arization and preserve existing vessels in vivo and are
ffective for treating ischemic vascular disease.
ultiple angiogenic factors are up-regulated after
D31 cells transplantation. To determine the effects
f CD31 cell transplantation on cytokine expression in
schemic hind limbs, mice were sacrificed and hind limb
issues collected. The expression levels of vascular endothe-
ial growth factor-A, angiopoietin-1, fibroblast growth
actor-2, stromal cell-derived factor-1, and CD31 were
ignificantly increased in the CD31 cell-injected limbs
ompared with the CD31– cell- or PBS-injected limbs
Fig. 5C). These data suggest that CD31 cell transplan-
ation up-regulates the expression of multiple biological
actors associated with neovascularization and bone mar-
enes Associated With Angiogenesis Significantly Up- or Down-RegTable 1 Genes Associated With Angiogenesis Significantly Up-
Probe Set ID Gene Symbol
7932985 NRP1 Neuropilin-1
7977046 TNFAIP2 Tumor necros
7991335 ANPEP Alanyl (memb
8095680 IL8 Interleukin-8
8108217 TGFBI Transforming
8140556 HGF Hepatocyte gr
8103399 PDGFC Platelet-derive
8119898 VEGFA Vascular endo
8156278 EDG3 Endothelial di
8017599 PECAM1 Platelet/endo
7970737 FLT3 Fms-related ty
8040473 RHOB Ras homolog
7973084 ANG Angiogenin
7969414 KLF5 Kruppel-like fa
7951686 IL18 Interleukin-18
8096160 ARHGAP24 Rho GTPase a
8092552 IGF2BP2 Insulinlike gro
8152297 ANGPT1 Angiopoietin-1
8064978 JAG1 Jagged-1
8137670 PDGFA Platelet-derive
7951351 PDGFD Platelet-derive
8099471 FGFBP2 Fibroblast gro
TPase  guanosine triphosphatase; mRNA  messenger ribonucleic acid.ow cell mobilization. wontribution of CD31 cells into vasculogenesis. We
urther sought to determine the potential and magnitude of
he contribution of CD31 cells to ECs’ generation or
asculogenesis. To track the transplanted cells, we intra-
uscularly injected 1  106 DiI-labeled CD31 cells
nto the ischemic hind limb of nude mice. Histologic
nalysis demonstrated that a larger part of the injected
D31 cells were concentrated in the pericytic or
erivascular areas (Figs. 6A to 6D, Online Video 1) and
smaller population of CD31 cells exhibited an EC’s
pecific marker, ILB4, within the vascular structure at 2
o 8 weeks (Figs. 6E to 6G, Online Video 2). This
uggests that CD31 cells generated ECs in vivo. To
onfirm this, we performed fluorescent in situ hybridiza-
ion (FISH) using human Y chromosome probe (25,26).
he FISH data showed that Y chromosome signals from
ransplanted human CD31 cells were detected within
he nuclei of ECs (Fig. 6I). Collectively, these data
ndicate that CD31 cells can give rise to ECs, suggest-
ng their vasculogenic potential.
uantitative analysis of endothelially transdifferentiated
D31 cells. It has been difficult to quantify the rate of
ifferentiation of BM-derived cells in vivo. Here, to more
ccurately quantify the number of functional ECs derived
rom transplanted CD31 cells, we conducted FACS
nalysis on enzymatically digested muscle following sys-
emic injection of fluorescein isothiocyanate-labeled
LB4. The FACS analysis revealed that 2.2  0.8% of
he cells were double positive for DiI and ILB4 at 4
d in CD31 Cells Compared to CD31 Cellswn-Regulated in CD31 Cells Compared to CD31 Cells
Description Fold Change
11.8
r, alpha-induced protein-2 7.4
minopeptidase 6.6
6.5
factor beta-induced 6.5
actor 5.8
th factor C 5.2
growth factor A 4.7
iation, sphingolipid G-protein coupled receptor-3 4.2
cell adhesion molecule-1 3.9
kinase-3 3.5
amily, member B 3.5
3.2
3
2.5
ng protein-24 2.4
ctor-2 mRNA binding protein-2 2.2
2.2
2.1
th factor alpha polypeptide 2
th factor D –2
ctor binding protein-2 –2.2ulateor Do
is facto
rane) a
growth
owth f
d grow
thelial
fferent
thelial
rosine
gene f
ctor-5
ctivati
wth fa
d grow
d grow
wth faeeks, suggesting that significant portion of functional
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August 10, 2010:593–607 Angio-Vasculogenic Properties of CD31 CellsFigure 3 In Vitro Vasculogenic Properties of CD31 Cells
(A, B) Uptake of 1,1=dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine-labeled acetylated low-density lipoprotein (red fluorescence) and binding to Ulex europaeus agglu-
tinin 1 lectin (green fluorescence) identified endothelial progenitor cells. CD31 cells gave rise to higher number of endothelial progenitor cells (A) and endothelial pro-
genitor cell colonies (B). n  5 per group. **p  0.01, Bars: 200 m. (C) Cell adhesion assay showed higher adhesion of CD31 cells thanCD31– cells to all tested
extracellular matrix proteins. n  5 per group. Bars: 200 m. (D) CD31 cells expressed endothelial proteins von Willebrand factor, kinase insert domain receptor, vas-
cular endothelial cadherin, and CD31 in culture with endothelial growth media 2 for 6 days. Bars: 200 m. Continued on next page.
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Angio-Vasculogenic Properties of CD31 Cells August 10, 2010:593–607Cs were derived from transplanted CD31 cells
Fig. 7A). Next, to further confirm whether these double
ositive cells were truly derived from the injected human
Figure 3 Continued
(E) Cultured CD31 cells formed vascular tubelike structures over the period of 3
were aggregated; at around day 10, the cells started to form tubular structures wi
phologic changes to form linear tubular structures, mimicking in vivo vasculogenes
(F) Various morphologies of tubular structures. Bars: 200 m. (G) Tubular structu
acetylated low-density lipoprotein (red fluorescence) and Ulex europaeus agglutinin
structures. Phase contrast images (left panels) and fluorescent microscopic imag
1,1=dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine-labeled acetylated low-densi
I, 100 m. (J) Temporal expression patterns of multiple angiogenic genes examin
CD31 cells over 28 days. n  5 per group. acLDL  acetylated low-density lipop
progenitor cells; FN  fibronectin; LN  laminin; VN  vitronectin; other abbreviatD31 cells, they were subjected to FISH with human Y ihromosome. FISH demonstrated that the ILB4- and
iI-positive cells from recipient mice were of human
onor origin, confirming differentiation of CD31 cells
. In the first week of culture under endothelial growth media 2, CD31 cells
e cell clusters; and between days 12 and 16, the cell clusters underwent mor-
rs: D8 and D10, 100 m; D12, D14, D16, and magnified image, 60 m.
owing uptake of 1,1=dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine-labeled
ding (green fluorescence). Bars: 200 m. (H, I) Enlarged images of tubular
w that the tubular structures are composed of multiple cells and take up
protein and are bound by Ulex europaeus agglutinin 1 lectin. Bars: H, 60 m;
real-time reverse transcriptase polymerase chain reaction during cultivation of
CL  type I collagen; DAPI  4=,6-diamidino-2-phenylindole; EPCs  endothelial
s in Figures 1 and 2.weeks
thin th
is. Ba
res sh
1 bin
es sho
ty lipo
ed by
rotein;
ions anto ECs (Fig. 7B).
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August 10, 2010:593–607 Angio-Vasculogenic Properties of CD31 Cellsiscussion
n this study, we show that CD31 is a unique and compre-
ensive marker to represent potent angiogenic and vasculo-
enic cells in human PB and that these cells are therapeu-
ically effective for recovering tissue from ischemia. First, we
emonstrated that human CD31 cells highly express
SC/HPC and EC markers. Second, CD31 cells are
nriched with proangiogenic genes. Third, compared with
D31– cells, CD31 cells generated more EPCs and
Figure 4 CD31 Cell Transplantation Is Effective for Recovery
(A, B) Recovery of blood perfusion in ischemic hind limbs. Laser Doppler perfusio
CD31 versus the CD31– and phosphate-buffered saline groups over 4 weeks afte
perfusion. n  9 per group. *p  0.05, **p  0.01, CD31 versus phosphate-bu
ischemic hind limbs. Representative photographs (C) and statistical analysis of lim
group than in the CD31– or the phosphate-buffered saline groups. Red circles ind
*p  0.05. PBS  phosphate-buffered saline.emonstrated EC differentiation and vascularlike tube for- eation in culture. Fourth, implantation of CD31 cells into
schemic hind limb enhanced recovery of tissue from isch-
mic injury and increased the rate of limb salvage as well as
he expression of angiogenic factors. Fifth, implanted
D31 cells show clear vasculogenic potential in ischemic
imb tissues.
Because CD31 is a ubiquitous endothelial marker, we
ested the hypothesis that the cells expressing CD31 in PB
ave angiogenic and/or vasculogenic capabilities. FACS
howed that the CD31 cells expressed HSC/HPC mark-
hemia and Preservation of Tissue in Hind Limb Ischemia
es (A) and quantitative analysis (B) showed improved blood perfusion in the
transplantation. The blue represents low perfusion and the red represents high
saline. †p  0.05, ‡p  0.01, CD31 versus CD31–. (C, D) Limb salvage in
s score (D) at day 28 showed significantly higher limb salvage in the CD31
mb loss, foot necrosis, toe necrosis, and intact limb. n  9 per group.of Isc
n imag
r cell
ffered
b los
icate lirs and well-known EC markers, suggesting dual properties
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Angio-Vasculogenic Properties of CD31 Cells August 10, 2010:593–607f CD31 cells. Unbiased microarray data and qRT-PCR
esults indicated that angiogenic and other genes beneficial
or vascular regeneration are highly enriched in the CD31
ell population. Another distinguishing feature of CD31
ells is that they gave rise to EPCs in the culture whereas
D31– cells did not. CD31 cells frequently formed
ascularlike tubes in culture without the aid of biomaterials
uch as Matrigel (BD Biosciences, San Jose, California),
imicking the developmental process of vascular tube
ormation from angioblasts or EPCs (Figs. 3E to 3I). This
nding is one of the most unprecedented of this study,
upporting the vasculogenic potential of CD31 cells.
hese data suggest that CD31 is an antigenic signpost for
Figure 5 CD31 Cell Transplantation Induced Neovascularizatio
(A, B) Capillary density in hind limb muscles. Isolectin B4 staining for ischemic hi
significantly increased number of capillaries in the CD31 group than in the CD31
0.01. (C) Compared with CD31– cell or phosphate-buffered saline injection, CD31
factors in tissues measured by real-time reverse transcriptase polymerase chain r
n  5 per group. *p  0.05; **p  0.01. SDF-1  stromal cell-derived factor-1; oobust proangiogenic and vasculogenic cells in PB. tIn vivo cell transplantation studies further confirmed
hese results. CD31 cell transplantation induced higher
xpressions of multiple paracrine factors in the ischemic
issues during the critical period of ischemia repair. Our
ata suggest that the major mechanism of CD31 cells
ould be a nondifferentiation mechanism because the
ate of endothelial differentiation was too small to ac-
ount for the magnitude of therapeutic effects seen.
D31 cells highly expressed crucial angiogenic and
rteriogenic factors including vascular endothelial growth
actor, angiopoietin-*1, fibroblast growth factor-2, and
onocyte chemoattractant protein-1. Synergistic effects
f these angiogenic factors have been reported to induce
Vivo
muscles (A) and the quantitative analysis of capillary density (B) demonstrated
phosphate-buffered saline groups. Bars: A, 100 m. n  8 per group. **p 
transplantation induced increased expression of angiogenic and chemoattractant
. Data are presented as fold difference to the phosphate-buffered saline group.
bbreviations as in Figures 2 and 4.n In
nd limb
– and
 cell
eaction
ther aherapeutic neovascularization (27). In addition, tissues
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August 10, 2010:593–607 Angio-Vasculogenic Properties of CD31 CellsFigure 6 Engraftment and Differentiation of Transplanted CD31 Cells Into ECs in Ischemic Hind Limbs
(A to D) Localization of CD31 cells in the perivascular regions. Confocal microscopic images showed that 1,1=dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine (DiI)-
labeled CD31 cells were more preferentially localized to the pericytic or perivascular areas (arrowheads). One colocalization with endothelial cells is shown by an
arrow. Bars: A, C, D, 10 m; B, 20 m. Continued on next page.
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(E to G) Endothelial cells differentiation of CD31 cells. Three-dimensional z-stacked orthogonal and multipanel images clearly demonstrated that a part of the engrafted
CD31 cells were incorporated into vascular structures and exhibit an endothelial cell marker, suggesting endothelial differentiation of CD31 cells. Green, isolectin B4;
Red, DiI-labeled CD31 cells; Blue, 4=,6-diamidino-2-phenylindole. Bars: E, 500 m; F, G, 10 m. (H, I) Fluorescent in situ hybridization on CD31 cell transplanted
hind limb tissues. One cell (H, arrowhead), which was localized at the pericytic area, exhibited red fluorescence for human Y chromosome. The other cell (I, arrows)
exhibited a fluorescent in situ hybridization signal (red) within the nuclei of an isolectin B4–stained capillary (arrows), suggesting differentiation of injected CD31 cells
into endothelial cells in vivo. Isolectin B4 (green), 4=,6-diamidino-2-phenylindole (blue). Bars: H, I, 100 m. ECs  endothelial cells; ILB4  isolectin B4; other abbrevia-
tion as in Figure 3.
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August 10, 2010:593–607 Angio-Vasculogenic Properties of CD31 CellsFigure 7 Verification and Quantification of ECs Generated From Transplanted CD31 Cells
(A) Hind limb tissues were harvested 4 weeks after injection with DiI-labeled CD31 cells and digested with an enzyme cocktail. The fluorescent-activated cell sorter
analysis showed that 2.2% of endothelial cells in hind limb muscles were derived from injected CD31 cells. P1 gating represents ILB4 fraction and P2 gating indi-
cates double positive population for DiI (CD31 cells) and isolectin B4 (endothelial cells). n  5. (B) Fluorescent-activated cell-sorted cells showing double positivity for
DiI and isolectin B4 were subjected to fluorescent in situ hybridization. Fluorescent in situ hybridization showed that these double positive cells derived from ischemic
hind limb of nude mice were of human origin. Bars: upper B, 200 m; lower B, 20 m. FACS  fluorescent-activated cell sorter; FISH  fluorescent in situ hybridization;
other abbreviations as in Figure 6.
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Angio-Vasculogenic Properties of CD31 Cells August 10, 2010:593–607njected with CD31 cells expressed high levels of
tromal cell-derived factor-1, which are known to con-
ribute to a pro-neovascularization environment. For
ptimal neovascularization, such an environment is re-
uired to recruit necessary cell types including monocytes
nd macrophages (28,29). Another characteristic that
ay make CD31 cells particularly effective is their high
dhesion capacity. Cell adhesion signals control cell
iability and are essential for regulated angiogenesis and
asculogenesis via cell– cell and cell–matrix interactions
9,11,15).
The controversy remains regarding the (trans)differen-
iation potential of BM-derived cells into ECs. To clarify
his, we meticulously evaluated hind limb muscles using
ultiple techniques. First, we used 3-dimensional recon-
truction of confocal microscopic images to examine at
east 1,200 tissue sections collected from 10 animals from
ach group. Although most CD31 cells were localized
o the interstitium or perivascular region, some cells were
ncorporated into vasculature and expressed functional
C markers (Fig. 7A). Second, FISH using Y chromo-
ome probes showed positive donor cell-derived signals
ithin the nuclei of ECs, suggesting endothelial differ-
ntiation of CD31 cells. Third, FACS analysis con-
rmed and quantified ECs derived from CD31 cells
njected into hind limb ischemia. The FACS analysis
evealed 2.2% of ECs in hind limb muscle were derived
rom implanted CD31 cells. We used these techniques
o avoid sampling errors inherent in histologic analysis. To the
est of our knowledge, this is the first study to employ this
echnology to prove and quantify endothelial differentiation
rom injected BM cells. Finally, we further confirmed that
hese FACS-isolated (trans)differentiated ECs are human
rigin by FISH. These results indicate that specific populations
f PB-MNCs can (trans)differentiate into ECs although the
ifferentiation efficiency is low.
Cell selection using the surface antigen CD31 has several
dvantages over more specific hematopoietic stem/progenitor
arkers CD133 or CD34 (30,31). Approximately 80% of
D133 cells and 85% of CD34 cells are contained
ithin the CD31 cell fraction (Fig. 1, Online Fig. 1).
hus, CD31 cells can exert most of the beneficial effects of
oth cell types while still providing additional paracrine or
ascularizing effects through other cell types. Clinically, as
D31 cells occupy approximately 30% of PB-MNCs,
hese cells do not require mobilization to obtain enough to
e used for cell therapy.
onclusions
B-derived CD31 cells contain robust angiogenic and
asculogenic abilities that ameliorate hind limb ischemia.
lthough we only showed ischemic limb recovery in this
tudy, this therapy would also be effective for ischemic heart
isease given their broad neovascularizing, paracrine, and
ell adhesion capacities. Accordingly, these cells can serve ashighly promising and novel therapeutic option for isch-
mic cardiovascular disease. Further investigation will be
eeded to determine if CD31 cells are capable of treating
uman ischemic cardiovascular diseases.
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